Links, January 16, 2026
·
Zach Ocean
- What makes Forever Chemicals forever? - Bryan Johnson
- Steady Progress and Self-Reflection: 2025 Annual Letter - Permanent Equity
- The emerging epicenter: Asia’s role in biopharma’s future - McKinsey
- Is Biopharma Doing Enough to Advance Novel Targets? - L.E.K. Consulting (via Jacob Kimmel’s Creating Therapeutic Abundance)
- moPPIt: De Novo Generation of Motif-Specific Peptide Binders - ChatterjeeLab
- moPPIt thread - @pranamanam
- Biotech Tycoon - Andrew White
- Antibodies are not magic bullets – more like sticky drunkards - Andrew George, The Conversation
- AI program could help guard against pandemics and biowarfare - ASU (Abhishek Singharoy)
- Origin-1: A Generative AI Platform for De Novo Antibody Design - Absci
- ARPA-H - Advanced Research Projects Agency for Health
- Axiom - Frontier AI systems to predict, explain and fix human toxicity risks better than animal testing
- Lila AI - Scientific Superintelligence ($500M raised)
- Anti-aging strategies and ex vivo rejuvenation - Cell Stem Cell
- Affinity maturation with linear regression - Cell Stem Cell
- Why is China winning biotech? - @zavaindar
- Biotech VC translations - @BowTiedBiotech
- drugCLIP - Science
- Merge Labs - New Sam Altman BCI company, @mikhailshapiro
- Are there accumulating microplastics in human tissue, or not? - Science